UCB: Additional Indications for Bimzelx Could Drive Growth as Generics Weigh on Portfolio

UCB released long-term safety and efficacy data for Bimzelx, demonstrating that most patients treated for moderate to severe plaque psoriasis achieved complete skin clearance at year four. The results from this long-term study further support the safety and efficacy profile for Bimzelx, which was approved by the US Food and Drug Administration in October 2023. UCB plans to continue the global launch of Bimzelx in Europe and Japan, and the positive long-term data should help increase patient uptake.